Jiangsu Aidea Pharmaceutical announced that one of the actual controllers and the Chairman, Fu Heliang, as well as Director and President Zhang Jie, plan to increase their shareholding in the company through the Shanghai Stock Exchange trading system starting from July 4, 2024 for a period of 6 months, with the total amount of shareholding not less than 5 million yuan and not exceeding 10 million yuan.
艾迪药业：实际控制人及总裁拟增持股份500万至1000万元
Jiangsu Aidea Pharmaceutical: The actual controller and president plan to increase their shareholding by 5-10 million yuan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.